Clinical Trials | October 23, 2025
Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
RPG Life Sciences has reported total income of Rs. 186.22 crore during the period ended September 30, 2025
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Expanding US operations to address the increased demand for API development and manufacturing
This new facility strengthens Latin America as a collaborative hub
Subscribe To Our Newsletter & Stay Updated
